SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ — Eye Level is hosting the 2025 Math Olympiad (ELMO 2025), inviting elementary and middle school students (grades 1 to 9) from around the world to showcase their math skills. The competition will run from November 8 to December 7, 2025, with schedules set according to each participating country across 16 regions: Australia, Hong Kong & Macau, India, Indonesia, Malaysia, Myanmar, New Zealand, the Philippines, Singapore, Taiwan, Thailand, the United Kingdom, the United States, Uzbekistan, and Vietnam.
Established in 2004, the Eye Level Math Olympiad is an annual competition designed to provide students with a valuable opportunity to assess and enhance their mathematical abilities. The competition challenges participants across key domains of arithmetic and problem-solving skills. Tailored to each grade level, the questions allow students to objectively evaluate their skills.
All participants will receive a certificate of participation and a comprehensive analysis of their test results. Official results and winners will be announced in January 2026 on globalelmo.com, with local award ceremonies planned to honor outstanding participants.
Eye Level is an international provider of supplemental education services in Math and English, with more than 1 million students worldwide experiencing its programs each year. Eye Level empowers students to learn at their own pace and achieve their goals. Through a growth-minded learning process, Eye Level helps students build strong learning habits that form the foundation of success in school and beyond.
Macau students participate in the Eye Level Math Olympiad (ELMO) 2024
– The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide groupcompared to 57.1% in the semaglutide monotherapy group.
– Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47 demonstrated a lower rebound effect after treatment discontinuation compared to the semaglutide monotherapy group, supporting the potential use of once-monthly ASC47 as a maintenance therapy.
HONG KONG, Sept. 22, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide, demonstrated up to 56.2% greater relative reduction in body weight on day 29 in participants with obesity (body mass index ≥ 30 kg/m2) compared to placebo in combination with semaglutide (semaglutide monotherapy).
ASC47-103 study (NCT06972992), conducted in the U.S., was a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of a single-dose, ultra-long-acting subcutaneously administered ASC47 in combination with four weekly doses of 0.5 mg semaglutide in participants with obesity, compared to volume-matched placebo in combination with four weekly doses of 0.5 mg semaglutide. The treatment duration was four weeks and the follow-up period was six weeks. The study, conducted in the U.S., enrolled 28 participants with obesity. Study objectives included evaluations of safety, tolerability, pharmacokinetics, assessment of weight losses of three different single doses (10 mg, 30 mg and 60 mg) of ASC47 in combination with four weekly doses of 0.5 mg semaglutide. The effect on fat and lean mass was not an objective of this study given the short treatment duration (28 days).
On day 29, a single SQ dose of 30 mg ASC47 in combination with four weekly doses of 0.5 mg semaglutide (N=6) demonstrated a 56.2% greater relative reduction in body weight compared to four weekly doses of 0.5 mg semaglutide monotherapy (N=7), and a single SQ dose of 60 mg ASC47 in combination with four weekly doses of 0.5 mg semaglutide (N=9) demonstrated a 15.1% greater relative reduction in body weight compared to four weekly doses of 0.5 mg semaglutide monotherapy (N=7). In a pooled patient analysis of both cohorts, ASC47 in combination with semaglutide (N=15) demonstrated a 31.6% greater relative reduction in body weight compared to semaglutide monotherapy (N=7). On day 29, four weekly doses of semaglutide monotherapy demonstrated a 2.5% reduction in body weight from baseline, consistent with the reported data in the literature. The 10 mg dose of ASC47 in combination with semaglutide did not show any additional decrease in body weight compared to semaglutide monotherapy. Target engagement to thyroid hormone receptor beta (THRβ) at the 10 mg dose of ASC47 as measured by sex hormone binding globulin (SHBG) was below the threshold required for clinical effect. However, both 30 mg and 60 mg ASC47 demonstrated significant target engagement to THRβ by the measurement of SHBG.
On day 29, there were significant reductions in low-density lipoprotein cholesterol (LDL-C) in 30 mg and 60 mg ASC47 group compared to semaglutide monotherapy group. 10 mg ASC47 group did not show significant reduction in LDL-C compared to semaglutide monotherapy group, suggesting again that the 10 mg dose of ASC47 was below the threshold required for clinical effect.
These topline clinical data are consistent with the results of animal studies previously conducted and reported by Ascletis (Press Release). In a head-to-head diet-induced obese (DIO) mouse study, a single dose of 3 mg/kg ASC47 (human equivalent dose of approximately 25 mg for 100 kg humans based on the body surface area conversion) in combination with semaglutide demonstrated a 56.7% greater relative reduction in body weight compared to semaglutide monotherapy. The combination efficacy of a single dose of 9 mg/kg ASC47 (human equivalent dose of approximately 75 mg for 100 kg humans based on the body surface area conversion) in combination with semaglutide was less than the combination efficacy observed in 3 mg/kg ASC47 with semaglutide.
In the ASC47-103 study, ultra-long-acting SQ depot formulation of ASC47 demonstrated an observed half-life of up to 30 days. As a result, ASC47 significantly reduced body weight rebound after treatment discontinuation. On day 57 (4 weeks after treatment discontinuation), 30 mg ASC47 group (N=6) demonstrated a 157.1% greater relative reduction in body weight compared to the semaglutide monotherapy group (N=7), and 60 mg ASC47 group (N=9) demonstrated a 110.4% greater relative reduction in body weight compared to the semaglutide monotherapy group (N=7). In a pooled patient analysis of both cohorts, ASC47 group (N=15) demonstrated a 129.9% greater relative reduction in body weight compared to the semaglutide monotherapy group (N=7). As expected, in the semaglutide monotherapy group, weight loss from baseline observed on day 29 (2.5%) rebounded 68% to only 0.8% four weeks after patients came off semaglutide treatment. These topline data support the potential use of once-monthly ASC47 monotherapy as a maintenance therapy.
The pharmacokinetic profiles of semaglutide and ASC47 in combination were consistent with those observed in their respective monotherapies (semaglutide in this study and ASC47 in a previous study). These topline data suggest that dose adjustments are not necessary when co-administered.
ASC47 in combination with semaglutide was safe and well tolerated. Table 1 summarizes the treatment-emergent adverse event (TEAE) profile of ASC47 in combination with semaglutide compared to semaglutide monotherapy. The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly improved compared to semaglutide monotherapy. The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group. Results of all thyroid function tests including thyroid stimulating hormone (TSH), free triiodothyronine (FT3), total triiodothyronine (TT3), free thyroxine (FT4) and total thyroxine (TT4) were within normal limits and no thyroid-related TEAEs were reported. All telemetry assessments and ECGs were within normal limits. No heart rate and QTc increases were observed.
In the current study, there were no titrations for semaglutide. The incidence rates of GI-related TEAEs of semaglutide monotherapy in the study are consistent with those reported in the literature in the absence of titration.
Table 1. The GI tolerability of ASC47 in combination with semaglutide was improved compared to semaglutide monotherapy
Category
30 mg ASC47 +
0.5 mg
semaglutide (N=6) n (%)
60 mg ASC47 +
0.5 mg
semaglutide (N=9) n (%)
30 mg/60 mg
ASC47 + 0.5 mg
semaglutide (N=15) n (%)
Placebo +
0.5 mg
semaglutide (N=7) n (%)
Number of participants
reporting at least one
TEAE
6 (100.0 %)
8 (88.9 %)
14 (93.3 %)
7 (100.0 %)
Number of participants
reporting SAEs
0 (0.0 %)
0 (0.0 %)
0 (0.0 %)
0 (0.0 %)
Overall discontinuation
0 (0.0 %)
0 (0.0 %)
0 (0.0 %)
0 (0.0 %)
Number of participants reporting TEAEs by severity
“As the first study to evaluate an adipose targeted THRβ agonist in combination with an incretin drug in participants with obesity, we’re very encouraged that the addition of ASC47, an adipose-targeting THRβ agonist, to an incretin regimen led to a significant synergy in terms of body weight reduction, yielding up to an additional 56.2% increase in efficacy, and a substantial improvement in GI tolerability,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “This study provides important proof-of-concept data that will further inform our Phase IIb combination study designs for multiple metabolic diseases such as obesity and metabolic dysfunction-associated steatohepatitis (MASH).”
Pending on the consultation with the U.S. Food and Drug Administration and other regulatory agencies, the Phase IIb combination studies may include once-monthly subcutaneously administered ASC47 (30 mg and 60 mg) in combination with ASC35, a once-monthly subcutaneously administered GLP-1 receptor (GLP-1R)/GIP-receptor (GIPR) peptide agonist, and once-daily oral version of ASC47 in combination with once-daily oral ASC30.
ASC35 is an in-house discovered and developed GLP-1R/GIPR peptide agonist. The pharmacokinetic data in non-human primates (NHP) predict ASC35 has much longer observed half-life in humans than tirzepatide, supporting once-monthly SQ dosing. Furthermore, the DIO mouse model demonstrated that ASC35 reduced more body weight than tirzepatide. More ASC35-related data will be released in the near future.
About ASC47-103 Study
The ASC47-103 study, conducted in the U.S., is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability and efficacy of single-dose, ultra-long-acting subcutaneously administered ASC47 in combination with semaglutide in participants with obesity (body mass index ≥ 30 kg/m2). The ASC47-103 study consists of three cohorts: Cohort 1 participants receive a single dose of 10 mg ASC47 (N=6), or volume-matched placebo (N=2) via SQ injection, and four doses of semaglutide (0.5 mg, once-weekly) via SQ injection. Cohort 2 participants receive a single dose of 30 mg ASC47 (N=6), or volume-matched placebo (N=2) via SQ injection, and four doses of semaglutide (0.5 mg, once-weekly) via SQ injection. Cohort 3 participants receive a single dose of 60 mg ASC47 (N=9), or volume-matched placebo (N=3) via SQ injection, and four doses of semaglutide (0.5 mg, once-weekly) via SQ injection. The treatment duration was four weeks and the follow-up period was six weeks.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
SINGAPORE, Sept. 22, 2025 /PRNewswire/ — Ecolab Inc., a global leader in sustainability solutions for water, hygiene, and infection prevention, has recognized Chandra Asri Group for its outstanding leadership and achievements in water conservation and energy optimization across operations in Indonesia and Singapore. The honor comes as part of the Ecolab Southeast Asia Impact Award, highlighting Chandra Asri Group’s exceptional impact and commitment.
Ecolab and Chandra Asri Group team in Singapore
(Left) Christophe Beck, Ecolab Chairman and CEO, with (Right) Erwin Ciputra, President Director and CEO of Chandra Asri Group and Aster
The award acknowledges Chandra Asri Group’s success in optimising water savings of more than 2 million cubic metres and delivering measurable energy efficiencies through innovative solutions and long-term collaboration with Ecolab. The recognition positions Chandra Asri Group as one of the region’s leading industrial champions advancing water circularity and sustainable resource management.
The accolade was presented during a high-level executive meeting in Singapore between Christophe Beck, Ecolab Global Chairman and CEO, and Erwin Ciputra, President Director and CEO of Chandra Asri Group and Aster.
Christophe Beck, Chairman & CEO of Ecolab Inc. said, “Chandra Asri Group and Aster are setting a powerful example of how innovation, partnership and purpose can deliver lasting impact for business and the planet. Their commitment to water circularity and energy efficiency reflects the kind of bold action required to build a more resilient future across Southeast Asia. Together, we’re proving that operational excellence, business growth and environmental progress don’t have to be mutually exclusive.”
Erwin Ciputra, President Director and CEO of Chandra Asri Group and Aster, said “Sustainability is the core of Chandra Asri Group’s transformation and growth journey. Our partnership with Ecolab has been instrumental in helping us advance water circularity and optimise resource efficiency. As we expand across Southeast Asia, we look forward to deepening this collaboration to deliver solutions that not only strengthen our operations but also contribute to a more resilient and sustainable future. Ecolab has been a valuable partner in helping us improve safety, optimize resource use and reduce environmental footprint.”
Diego Trujillo, VP & GM for Downstream Ecolab Southeast Asia, shared, “We’re proud of the long-standing partnership with Chandra Asri Group in Singapore and Indonesia and excited for regional collaborations for sustainable growth. The teams from both organizations have expertise and exceptional dedication to delivering operational excellence, continuous improvements, and putting safety first.”
The partnership continues to expand across strategic areas, reinforcing both companies’ commitment to advancing sustainable innovation in the region:
Water Circularity: Reducing, reusing, and reclaiming water across business operations, to address water scarcity and minimise reliance on freshwater resources
Sustainable Growth through Water-Energy Nexus: Optimising water use and reducing the energy required for moving water, heating, cooling, and pumping
Innovation and Digital Transformation: Leveraging real-time monitoring and advanced water technologies to enhance efficiency, performance and resilience
Notably, Ecolab has developed a wastewater treatment facility in Singapore on Aster Chemicals & Energy Jurong Island with a capacity to treat and reuse up to 24,000 cubic meters of wastewater each month.
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. For more information, visit www.ecolab.com.
Chandra Asri Group is a leading provider of energy, chemical, and infrastructure solutions in Southeast Asia, supplying products and services to various manufacturing industries in both domestic and international markets. Since the Group’s establishment in 1992, Chandra Asri has grown from strength to build our reputation as a reliable growth partner, with strategically well positioned assets in Indonesia and Singapore. The Group’s asset base includes a refinery with a capacity of 237,000 barrels per day alongside a 1.1 million metric ton per annum ethylene cracker on Bukom Island, 2.5 million metric ton per annum downstream chemicals on Jurong Island and Indonesia’s one and only naphtha cracker located in Cilegon with a capacity of 0.9 million metric ton per annum. The Company’s business is supported by core infrastructure assets, including energy, water, ports & storage, and logistics. For more information, visit www.chandra-asri.com.
About Aster
Aster Group is a leading provider of energy, chemical, and infrastructure solutions in Southeast Asia, supplying products and services to various manufacturing industries in both domestic and international markets. It is a Chandra Asri-led joint venture with Glencore. Since Chandra Asri Group’s establishment in 1992, the Group has grown from strength to strength to build its reputation as a reliable growth partner, with strategically well positioned assets in Indonesia and Singapore. The Group’s total asset base includes a refinery with a capacity of 237,000 barrels per day alongside a 1.1 million metric ton naphtha cracker on Bukom Island, 2.5 million metric tons of downstream chemical assets on Jurong Island, and a 0.9 million metric ton naphtha cracker in Cilegon. The company’s business is supported by core infrastructure assets, including energy, electricity, water, jetty, and tank farm facilities. For more information, visit www.aster.com.sg.
Event offers Japanese beauty experts access to more than 700 suppliers, hands-on formulation lessons and insights into global beauty trends
TOKYO, Sept. 22, 2025 /PRNewswire/ — in-cosmetics Asia, the leading event in Asia-Pacific for personal care ingredients, will take place at BITEC, Bangkok from 4-6 November 2025. Bringing together more than 700 leading ingredient suppliers, cosmetic scientists, formulators and manufacturers from across the globe, the event, organised by RX, will offer Japanese professionals the unique opportunity to strengthen their supply chains and gain insights into the global trends reshaping the industry.
Sarah Gibson, Event Director of in-cosmetics Asia, said: “Japanese consumers expect nothing less than perfection, but the market is becoming much more complex with demographic shifts and fierce competition from international players such as South Korea, China, India, Indonesia and the US.
“To stay ahead, Japanese beauty professionals need to diversify their supply chain, embrace new ways of thinking, ensure product safety and stability, and stay ahead of global beauty trends. in-cosmetics Asia 2025 will provide the tools, resources and connections to achieve exactly that – so that J-Beauty can continue its tradition of quality and excellence, while securing its future growth.”
Whilst Japan’s beauty market remains one of the most sophisticated in the world, 2025 research by Euromonitor International shows that overall sales are not projected to return to 2019 levels, and the competitive landscape is intensifying.
International luxury brands are re-entering Japan, while agile markets like K-beauty and C-beauty are staying ahead of market trends, launching products at speed and capturing the attention of younger consumers.
in-cosmetics Asia 2025 will equip Japanese professionals with the right tools and knowledge needed to secure future market growth:
Meet more than 700 international ingredient suppliers, diversifying supply chain and expanding sourcing options
Discover the latest raw materials, active ingredients and formulation technologies before they reach the wider market
Gain knowledge from an insight- and data-led conference programme, featuring speakers from L’Oréal, Mageline, Amorepacific, Raine Beauty and many more, offering practical insights to help brands respond to quickly evolving consumer demands
Develop practical skills through hands-on Formulation Lab sessions and in-depth Technical Seminars, designed to address the challenges of product development
Access exclusive insights into global trends such as clean beauty, sustainability, biotechnology, well-ageing and many more, shaping the future of the pan-Asian and global beauty markets
Build connections with leading scientists, R&D experts, suppliers and brand owners from across APAC, Europe, the US, and beyond.
in-cosmetics Asia, organised by RX, offers visitors the opportunity to learn in real time about current and emerging trends, gaining the skills and knowledge needed to strengthen their expertise in a competitive market. The 2025 event takes place from 4-6 November at BITEC, Bangkok. For more information and to register to attend, visit the website here.
About RX
RX is a global leader in events and exhibitions, leveraging industry expertise, data, and technology to build businesses for individuals, communities, and organisations. With a presence in 25 countries across 41 industry sectors, RX hosts approximately 350 events annually. RX is committed to creating an inclusive work environment for all our people. RX empowers businesses to thrive by leveraging data-driven insights and digital solutions. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.rxglobal.com.
About RELX
RELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and has offices in about 40 countries. It employs more than 36,000 people over 40% of whom are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York stock exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. *Note: Current market capitalisation can be found at http://www.relx.com/investors
SHANGHAI, Sept. 22, 2025 /PRNewswire/ — WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends.
So far this year, to enhance shareholder value, WuXi AppTec has distributed a total of RMB4.88 billion in cash dividends to investors through its annual dividend, special dividend and interim dividend. The Company’s cash dividends, combined with share repurchases and cancellations implemented this year, total RMB6.88 billion, representing over 70% of the net profit attributable to the owners of the Company in 2024.
For A-share shareholders, please refer to the Company’s announcement HERE. For H‑share shareholders, please refer to the Company’s announcement HERE.
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.
BEIJING, Sept. 22, 2025 /PRNewswire/ — A news report from CRI Online:
On September 18, the 22nd China-ASEAN Expo hosted a ceremony in Nanning, Guangxi, where, in all, 155 projects were finalized, including 94 industrial agreements, 44 initiatives applying AI across multiple sectors, and 17 international economic and trade deals.
Signing ceremony (Photo courtesy of Guangxi Zhuang Autonomous Region Park Development and Investment Promotion Service Center)
This year’s signing ceremony focused on the theme of “AI Taking Center Stage, Companies as Key Players.” It emphasized creating an international hub for artificial intelligence cooperation with ASEAN, strengthening cross-regional and cross-border industrial and supply chains, and securing a series of landmark agreements.
Organizers said the 44 AI-related initiatives span the foundational, technological, and application layers of artificial intelligence, in areas including manufacturing, services, agriculture, and the cultural and tourism industries. These initiatives are expected to deepen China-ASEAN cooperation through AI.
The international economic and trade agreements signed this year involve six ASEAN countries: Vietnam, Malaysia, Myanmar, Laos, Cambodia, and Indonesia. One example is the China-Laos AI Innovation Cooperation Center project, which will cover both construction and operation. The foreign-invested projects encompass integrated intelligent production of specialty agricultural products, biofuels, and paper processing.
Most notably, 45 projects were each valued at more than 1 billion yuan, spanning renewable energy, advanced equipment, metals processing, critical minerals, biomedicine, commercial space, low-altitude aviation and textiles. Among them were two projects worth over 10 billion yuan and three ranging from 5 billion yuan to 10 billion yuan.
XI’AN, China, Sept. 21, 2025 /PRNewswire/ — A news report from CRI Online:
A photo taken at the Forum
On September 17, 2025, the World Internet Conference Cultural Heritage Digitalization Forum opened in Xi’an, Shaanxi Province. Themed “Bridging History Through Digitalization, Building Civilization with Intelligence — Jointly Building a Community with a Shared Future in Cyberspace”, the forum aims to strengthen exchanges and dialogues, build broad consensus, and better empower the protection and inheritance of cultural heritage through digitalization, in order to inject profound and enduring cultural strength into the fostering of a community with a shared future in cyberspace.
Following the opening ceremony, the main forum was held where participants engaged in in-depth discussions on four topics: “Protection & Inheritance,” “Technology & Innovation,” “Industry & Empowerment,” and “Openness & Collaborative Governance”. The discussions focused on exploring new methods and pathways of digital empowerment for cultural heritage protection and promoting exchanges and mutual understanding among civilizations. Side events during the forum included an exhibition of selected digital cultural heritage projects, a thematic meeting of the WIC Digital Culture Heritage Working Group, and a training workshop on digital cultural heritage protection. The World Internet Conference Culture Heritage Digitalization Case Collection (2025) was also released during the main forum.
The event is hosted by the World Internet Conference (WIC) and organized by the People’s Government of Shaanxi Province. Approximately 800 guests from over 50 countries and regions, as well as 9 international organizations, attended the forum.
Empowering residents and patients with details on calorie count and macronutrients for every dish
SINGAPORE – Media OutReach Newswire – 21 September 2025 –Today, NHG Health and Tanoto Foundation jointly launched a cookbook titled, ‘I Can’t Believe It Tastes So Good’ – featuring 100 healthy recipes inspired by Chinese, Malay, Indian, Western and other cuisines, a nod to Singapore’s rich cultural diversity as the nation celebrates SG60. In conjunction with the cookbook launch, NHG Polyclinics, the primary care arm of NHG Health, organised a cooking demonstration, which brought together residents and patients to learn about healthier cooking tips from dietitians and patient advocates, as well as healthy lifestyle habits.
(Left to right) Associate Professor Karen Ng, Chief, Primary Care, Population Health, NHG Health, Chief Executive Officer, NHG Polyclinics; Mr Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies, Adviser to Sembawang GRC GROs (Sembawang Central); Ms Belinda Tanoto, Member, Board of Trustees, Tanoto Foundation; and Professor Benjamin Seet, Group Chairman Medical Board (Research) and Co-chair, Academic Partnership Office, NHG Health, launching the healthy cookbook ‘I Can’t Believe It Tastes So Good!” at NHG Sembawang Polyclinic.
2 The event was graced by Mr Ong Ye Kung, Minister for Health, Coordinating Minister for Social Policies, and Adviser to Sembawang Group Representation Constituency Grassroots Organisations (Sembawang Central). It was held at the NHG Sembawang Polyclinic Health and Wellness Studio located within Bukit Canberra, an integrated sports and community hub.
3 Launching the ‘I Can’t Believe It Tastes So Good’ cookbook, Minister Ong Ye Kung, said, “Healthy eating is one of the best forms of preventive care. When residents and patients make better food choices together, we not only improve personal well-being but also form friendships and strengthen community bonding. I hope this cookbook can play a positive part in this process.”
4 ‘I Can’t Believe It Tastes So Good’ cookbookis jointly funded by NHG Health Fund and Tanoto Foundation under the NHG Health Diabetes Reversal Programme. Its recipes are specially curated by clinicians and dietitians from NHG Polyclinics and nutritionists from Temasek Polytechnic, based on feedback from patients and community volunteers who participated in tasting sessions or tried these recipes at home. The cookbook offers practical easy-to-follow meals for every occasion and for everyone, especially those managing diabetes and other chronic conditions.
5 “This collaborative cookbook shows how primary care professionals, patients and the community can come together to promote healthy living and build a healthier Singapore. Designed and curated as a key resource for residents and patient empowerment, the cookbook is more than just a collection of healthy recipes; it serves as a bridge connecting families through the shared joy of cooking and creating memories together,” said Associate Professor Karen Ng, Chief of Primary Care, Population Health, NHG Health, and Chief Executive Officer, NHG Polyclinics.
6 “Diabetes is one of the biggest health challenges in Singapore today,” said Belinda Tanoto, Member of the Board of Trustees, Tanoto Foundation. “We’re excited to launch this cookbook with NHG Health to show that healthy food can be simple, tasty, and easy to prepare. With small changes, we hope more Singaporeans can enjoy healthier meals and build lasting habits.”
7 “Diabetes remains a major health challenge for Singapore. The goal of NHG Health is to not only bring the disease under control and to prevent its complications, but to empower individuals to better manage their health. This cookbook is an example of how we bring real-world solutions directly into homes and kitchens, and our commitment to adding years of healthy life for our population,” said Professor Benjamin Seet, Group Chairman Medical Board (Research), NHG Health.
8 Serving as a resource, the ‘I Can’t Believe It Tastes So Good’ cookbookprovides useful details of key nutrients for every dish. Each recipe has been thoughtfully planned to include ample protein, vitamins and fibre (e.g. colourful vegetables), and lower saturated fat, sugar and sodium content to suit different levels of calorie intake required at every stage of life, including those managing chronic conditions like diabetes and high blood pressure, while preserving the flavours of the dishes. The recipes also use simple, fresh ingredients paired with herbs and spices to create meals that are both nutritious and full of flavours, a key highlight of the cookbook.
9 With its launch, NHG Polyclinics’ family physicians, dietitians and nurses will use the cookbook to guide patients to specific recipes to reinforce the importance of healthy eating as part of their patient’s health and treatment plan. Patients will be taught how to plan their meals by mixing and matching the recipes to suit their nutritional needs for better health goals. For instance, the elderly will be guided on choosing recipes that are higher in protein and rich in fibre, and lesser in saturated and trans-fat and sodium to support muscle health, digestion and overall vitality while those with weight concerns will be guided to select the low-calorie recipes. The recipes will also be used at cooking workshops conducted by the Patient Advisory Council members and patient volunteers at the Health Studios located at NHG Polyclinics. It is available to members of the public at https://for.sg/2025-healthy-cookbookto inspire more people to share healthier home-cooked meals with family and friends.
10 “As a dietitian, I often see patients who struggle to eat a balanced meal. One of the reasons is not knowing how to choose healthier ingredients and their limited understanding of food nutrients that the body requires. With this cookbook, it makes it easy for those with dietary restrictions to plan their daily meals. We hope the cookbook can create a rippling effect, inspiring more people to cook their own meals and eat healthier,” said Pauline Xie, Principal Dietitian and Assistant Director of Clinical Services, NHG Polyclinics.
Name Glossary
Associate Professor Karen Ng
Chief, Primary Care, Population Health, NHG Health;
Chief Executive Officer, NHG Polyclinics
黄明燕副教授
总主任,基层医疗,国民保健,
国立健保集团;
行政总裁
国立健保集团综合诊疗所
Belinda Tanoto
Member of the Board of Trustees,
Tanoto Foundation
陈昱廷
董事会成员
陈江和基金会
Professor Benjamin Seet
Group Chairman Medical Board (Research),
NHG Health
薛寒友教授
集团医疗委员会主席(医学研究)
国立健保集团
Ms Pauline Xie
Principal Dietitian
Assistant Director, Clinical Services
NHG Polyclinics
谢欣盈
首席营养师
副处长, 医疗事务处
国立健保集团综合诊疗所
NHG Health Fund
国立健保集团基金
NHG Polyclinics
国立健保集团综合诊疗所
Poliklinik Kumpulan Jagaan Kesihatan Nasional
Nasional
Hashtag: #NHGHealth
The issuer is solely responsible for the content of this announcement.
About NHG Health
NHG Health is a leading public healthcare provider in Singapore recognised for its quality clinical care and its commitment in enabling healthier lives through preventive health, innovative solutions and person-centred programmes tailored to every life stage. Our integrated health system, which spans primary care, hospitals and national specialty centres, includes Tan Tock Seng Hospital, Khoo Teck Puat Hospital, Woodlands Health, Yishun Community Hospital, NHG Polyclinics, the Institute of Mental Health, National Skin Centre and the National Centre for Infectious Diseases.
Together with academic and industry partners, we advance medical education, research and healthcare innovation in Singapore, addressing areas that are critical to Singapore’s population needs. As the Regional Health Manager for Central and North Singapore, NHG Health partners general practices and health and social care agencies to ensure the physical, mental and social well-being of residents in the community.
Together, we are committed to building healthier and resilient communities, and Adding Years of Healthy Life to the people we serve.
NHG Polyclinics is the primary care arm of NHG Health, the regional health manager for the 1.5 million residents of Central and North Singapore.
NHG Polyclinics provides a comprehensive range of health services for the family, functioning as a one-stop health centre providing treatment for acute medical conditions, management of chronic diseases, women and children health services and dental care. The focus of NHG Polyclinics’ care is on health promotion and disease prevention, early and accurate diagnosis, disease management through physician led team-based care as well as enhancing the capability of Family Medicine through research and teaching.
Through the Family Medicine Academy and the NHG Family Medicine Residency Programme, NHG Polyclinics plays an integral role in the delivery of primary care training at medical undergraduate and post-graduate levels. The Primary Care Academy provides a one-stop primary care training centre for primary healthcare professionals and the community.
About Tanoto Foundation
At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyze systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes.
In Singapore, Tanoto Foundation’s work focuses on four key areas: medical research, early childhood education and development, leadership development, and community development with the aim of improving lives.
Since 2009, Tanoto Foundation has provided catalytic funding to advance scalable healthcare and medical research initiatives. By leveraging Singapore’s world-class medical research ecosystem and integrated academic healthcare landscape, we have supported pioneering projects that generate evidence, inform policy, and deliver real-world solutions for patients and families.
www.nhg.com.sg
Facebook
Instagram 
LinkedIn
TikTok
